A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care

NCT03711162 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

525

Enrollment

INDUSTRY

Sponsor class

Stopped The benefit-risk profile no longer supports continuing the study

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG: GLPG1690
DRUG: Placebo

Sponsor

Lakefront Biotherapeutics NV